Example Treatment Initiation Checklist for RADICAVA ORS® (edaravone).Download
Starting RADICAVA ORS® or RADICAVA® IV
This page organizes the process for starting patients on treatment into these steps:
The Benefit Investigation and Enrollment Form (BIF)
When you are considering starting a patient on RADICAVA ORS® or RADICAVA® IV, it is important to begin with the Benefit Investigation and Enrollment Form (BIF) as soon as possible, as it begins the investigation into your patient's insurance coverage.
When completing the BIF, be sure to provide:
Patient and your office information
Proper insurance information or a copy of your patient's insurance card(s)
Prescription information for RADICAVA ORS® or RADICAVA® IV
- You may indicate a preferred formulation in Section 3, Prescription Information
- Please check both boxes if you do not have a preference
Your signature and date of prescription
Patient authorization with a signature from patient or their Legal Representative
To help avoid unnecessary delays in patient access to therapy, provide documentation typically required for Prior Authorization.a (see footnote)
The BIF can be completed 2 waysb (see footnote)
Online within the Healthcare Provider (HCP) Portal
You may complete, sign, and submit the enrollment form online to the JourneyMate Support Program™.
Access the BIF at www.RadicavaOnlineEnrollmentForm.com
Follow instructions for completing, signing, and submitting the online form.
Register for an HCP portal account:
- Your office can enroll patients online
- Access a patient information dashboard
- See User Guide for more information
By Mail or Fax
If you have access to a printer, you may submit a completed and signed BIF to the JourneyMate Support Program™ via mail, fax, or electronic fax.
Download and save the editable BIF
Print, sign, scan or photograph, and submit the completed form using:
JourneyMate Support Program™
Insurance & Access Specialist
680 Century Point
Lake Mary, FL 32746
Completing a BIF, which includes your patient's signature, also enrolls your patient in the JourneyMate Support Program™c (see footnote)
If a patient or their Legal Representative is not available to sign the BIF, the patient or their Legal Representative has options for submitting a signed Patient Authorization Form:
An Insurance & Access Specialist can:
Email a link to the patient or their Legal Representative to eSign
Mail the form to the patient or their Legal Representative to return by fax or USPS mail
The patient or their Legal Representative can also download print, complete, and sign the Patient Authorization Form and submit it by fax or mail to the number or address listed above.
NOTE: As a reminder, all covered entities are obligated under the Health Insurance Portability and Accountability Act of 1996 (HIPAA) to have a business associate agreement (BAA) in place with any service provider that handles protected health information (PHI) on their behalf. This includes, among others, electronic data transmission services such as eSign and electronic fax services. Please refer to each service provider's website for more information regarding BAAs and PHI.
Restrictions apply. See Healthcare Provider Disclaimer.
The coverage determination process is based on the formulation of edaravone
For patients with commercial coverage, Medicare Advantage (Part C), or Medicare Part D, Prior Authorization is typically required.
Download the Steps for Patient Access to Edaravone flashcard that helps you understand how to start a patient on edaravone or switch a patient to their preferred formulation.
For RADICAVA ORS®
For patients with commercial coverage, Medicare Advantage (Part C), or Medicare Part D, Prior Authorization may be required
The Insurance & Access Specialist provides your office and your patient a preliminary benefit summary. Based on the summary, the prescription is triaged to an in-network specialty pharmacy.
Download the Accessing RADICAVA ORS® (edaravone) Through a Specialty Pharmacy flashcard that provides more information about how the specialty pharmacies provide RADICAVA ORS®.
For RADICAVA® IV
After the enrollment process is complete, the dedicated Insurance & Access Specialist is available to help investigate a patient's health insurance coverage and health plan benefits
Use the ALS Care Locator to help patients find sites convenient for them
The infusion provider submits any additional required information to the patient's health plan
The Insurance & Access Specialist contacts the patient to discuss financial support options that may be available, if eligible
When approval of coverage is confirmed, the infusion provider schedules the patient's treatment with RADICAVA® IV
Restrictions apply. See Prior Authorization Disclaimer.
If RADICAVA ORS® or RADICAVA® IV is denied by their health plan, you and your patient may request an exception from the health plan for coverage of the preferred formulation.
Limited exceptions and appeals assistanced (see footnote)
If the Prior Authorization is denied by the patient's health plan, an Insurance & Access Specialist may be able to provide limited assistance.
Sample Letter of Medical Necessity
This letter provides rationale for treatment with RADICAVA ORS® or RADICAVA® IV . It can help when filing appeals.Download Sample Letter of Medical Necessity
Sample Exceptions Letter
This letter can be used as part of a coverage determination to make a formal request for an exception when your patients health plan does not cover a treatment or healthcare service.Download Sample Exceptions Letter
An Insurance & Access Specialist does not fill out any information that requires the medical judgment of the prescriber, and only the prescriber can determine whether to pursue a Prior Authorization. Determination of Prior Authorization is at the sole discretion of the health plan. An Insurance & Access Specialist and Mitsubishi Tanabe Pharma America, Inc. do not assume responsibility for, nor do they guarantee the approval of a Prior Authorization request.
The dedicated Insurance & Access Specialist is ready to help process a script for the preferred formulation when coverage has been determined.
If you have been notified that RADICAVA ORS® or RADICAVA® IV is not covered by the patient’s health plan, a helpful guide called Considerations for Understanding Coverage Determination is available through your Mitsubishi Tanabe Pharma America Manager of Patient Access.
Getting patients on treatment
Prescription Fulfillment for RADICAVA ORS®
With coverage approval from the patient's health plan, the specialty pharmacy completes the prescription process:
Prescriber submits any additional required information to the specialty pharmacy, including Prior Authorization requirements.
Specialty pharmacy may help your office obtain a final coverage determination from the patient’s health plan.
Insurance & Access Specialist contacts the patient to discuss financial support options that may be available, if eligible.
When approval of coverage and payment are confirmed, specialty pharmacy applies available financial support, if eligible, and schedules delivery to the patient.
Patient takes RADICAVA ORS® at home.
Ordering RADICAVA® IV
After you have completed the BIF, your patient will be enrolled in the JourneyMate Support Program™ and a Patient ID will be assigned. You may place all subsequent orders for RADICAVA® IV using their Patient ID to complete the Order Form for Buy and Bill.
JourneyMate Support Program™
Insurance & Access Specialist
680 Century Point
Lake Mary, FL 32746
For questions about ordering RADICAVA® IV, call the JourneyMate Support Program™ Insurance & Access Specialist at 1-844-772-4548.
FOR RADICAVA® IV: Scheduling Infusions
The chosen site of care schedules the infusion with your patient. Remind your patients of the importance of staying on therapy and continuing to receive their infusions as prescribed.
For patients who served in the military, see the Getting Started For Veterans page.
aMay include, but are not limited to Letter of Medical Necessity, date of diagnosis, functional rating score information, and percent forced vital capacity (%FVC). Return to content
bMitsubishi Tanabe Pharma America, Inc. ("MTPA") is not affiliated with any electronic fax service providers (collectively, "service providers"). No fees or remuneration of any kind have been or will be exchanged with any healthcare provider for use of these service providers. Return to content
cA patient cannot be enrolled in the JourneyMate Support Program™ without patient authorization, which can be found on the Benefit Investigation and Enrollment Form, or a separate signed Patient Authorization Form for RADICAVA® on file. In addition, a Benefit Investigation and Enrollment Form must be submitted for each patient for whom treatment with RADICAVA® is requested.
Mention of these service providers does not constitute a referral, recommendation, endorsement of a particular service provider, and similarly, the absence of a service provider's name should not be construed as a negative comment from MTPA about that service provider. MTPA, as well as its employees or agents, shall not be held liable for any damages or harm resulting from any use or reliance on these service providers, and MTPA may modify its policy regarding these service providers at any time without notice. Return to content
dThe JourneyMate Support Program™ does not fill out any information that requires the medical judgment of the prescriber, and only the prescriber can determine whether to pursue a Prior Authorization. Determination of Prior Authorization is at the sole discretion of the health plan. The JourneyMate Support Program™ and Mitsubishi Tanabe Pharma America, Inc. do not assume responsibility for, nor do they guarantee the approval of a Prior Authorization request. Return to content